| Bioactivity | Fevipiprant (QAW039, NVP-QAW039) is s an orally active, selective, reversible prostaglandin D2 (DP2) receptor antagonist with an Kd value of 1.14 nM. Fevipiprant has the potential for the research of bronchial asthma[1][2][3]. | ||||||||||||
| Invitro | Fevipiprant (0-10 µM) inhibits the gene expression of IL-4, IL-3, IL-5, IL-8, CSF1, CSF2 in n in human Th2 cells induced by activated mast cell supernatants[1]. | ||||||||||||
| In Vivo | Fevipiprant (10 mg/kg; in the drinking water) reduces CaCl2-induced AAA (abdominal aortic aneurysm) formation in mouse[3]. Animal Model: | ||||||||||||
| Name | Fevipiprant | ||||||||||||
| CAS | 872365-14-5 | ||||||||||||
| Formula | C19H17F3N2O4S | ||||||||||||
| Molar Mass | 426.41 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Brightling C, et al. The pharmacology of the prostaglandin D2 receptor 2 (DP2) receptor antagonist, fevipiprant. Pulm Pharmacol Ther. 2021 Jun;68:102030. [2]. Lee HY, et al. Blockade of thymic stromal lymphopoietin and CRTH2 attenuates airway inflammation in a murine model of allergic asthma. Korean J Intern Med. 2020 May;35(3):619-629. [3]. Weintraub NL, et al. Role of prostaglandin D2 receptors in the pathogenesis of abdominal aortic aneurysm formation. Clin Sci (Lond). 2022 Mar 18;136(5):309-321. |
Fevipiprant
CAS: 872365-14-5 F: C19H17F3N2O4S W: 426.41
Fevipiprant (QAW039, NVP-QAW039) is s an orally active, selective, reversible prostaglandin D2 (DP2) receptor antagonist
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.